| Literature DB >> 34652633 |
Fumiaki Jinnouchi1, Yasuo Mori1, Goichi Yoshimoto1, Takuji Yamauchi1, Takuya Nunomura1, Ayano Yurino1, Masayasu Hayashi1, Junichiro Yuda1, Takahiro Shima1, Jun Odawara1, Shuichiro Takashima1, Kenjiro Kamezaki1, Koji Kato1, Toshihiro Miyamoto1, Koichi Akashi1, Katsuto Takenaka2.
Abstract
Post-transplant cytomegalovirus (CMV) disease can be almost completely avoided by current infection control procedures. However, CMV reactivation occurs in more than half of patients, and some patients can develop clinically resistant CMV infections. Whether resistance is due to the host's immune status or a viral resistance mutation is challenging to confirm. Therefore, a prospective observational analysis of refractory CMV infection was conducted in 199 consecutive patients who received allogeneic hematopoietic stem cell transplantation at a single institution. Among them, 143 (72%) patients received anti-CMV drugs due to CMV reactivation, and only 17 (8.5%) exhibited refractory CMV infection. These patients had clinically refractory infection. However, viral genome analysis revealed that only one patient exhibited a mutation associated with the anti-CMV drug resistance. Clinical resistance was mainly correlated with host immune factors, and the incidence of resistance caused by gene mutations was low at the early stage after a transplantation.Entities:
Keywords: Allogeneic hematopoietic stem cell transplantation; Drug resistance; Refractory cytomegalovirus infection; Viral genome analysis
Mesh：
Year: 2021 PMID： 34652633 DOI： 10.1007/s12185-021-03218-3
Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490